UnknownPhase 2NCT01556477

The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Nordic MDS Group
Principal Investigator: Lars Möllgård, MD, PhD
Nordic MDS Group
Intervention: Azacitidine(drug)
Enrollment: 72 target
Eligibility: 18 years · All sexes
Timeline: 2012 – 2014

Study locations (1)

Lars Möllgård, Stockholm, Sweden

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01556477 on ClinicalTrials.gov

Other trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE3NCT03223961
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
Groupe Francophone des Myelodysplasies

See all trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality →

← Back to all trials